Targets › RXRB
4 programs from 4 companies in 5 trials: 4 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Mar 2027.
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. (UniProt, P28702)
Open in Phaseline: the race on RXRB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Children's Hospital Medical Center, Cincinnati | Vitamin A Retinoid receptor ligand; immunomodulatory effects on T cell differentiation and GVHD | RXRA, RXRB, RXRG, RARA, RARB | Phase 2 | Graft Vs Host Disease | Aug 2027 |
| Memorial Sloan Kettering Cancer Center | Bexarotene Retinoid X receptor agonist | RXRB, RXRG, RXRA | Phase 1 | Cutaneous T-cell Lymphoma | Mar 2027 |
| SciTech Development | ST-001 nanoFenretinide (Fenretinide) Retinoid X receptor (RXR) agonist; pro-apoptotic retinoid with activity in lymphomas | RXRA, RXRB, RXRG | Phase 1 | Small Cell Lung Cancer; T-cell Lymphoma | May 2027 |
| The Methodist Hospital Research Institute | All-Trans Retinoic Acid (ATRA) Retinoid acid receptor (RAR/RXR) agonist | RXRA, RXRB, RXRG | Phase 1 | Multiple Myeloma | Jul 2029 |
Cutaneous T-cell Lymphoma (1) Small Cell Lung Cancer (1) T-cell Lymphoma (1) Multiple Myeloma (1) Graft Vs Host Disease (1)
small molecule (4)
Memorial Sloan Kettering Cancer Center (1) SciTech Development (1) The Methodist Hospital Research Institute (1) Children's Hospital Medical Center, Cincinnati (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.